Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 237.50
Bid: 237.50
Ask: 238.50
Change: 3.50 (1.50%)
Spread: 1.00 (0.421%)
Open: 233.00
High: 238.50
Low: 230.50
Prev. Close: 234.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PRTC to Present at Virtual Needham Conference

14 Apr 2020 07:00

RNS Number : 4591J
PureTech Health PLC
14 April 2020
 

14 April 2020

PureTech Health plc

 

PureTech to Present at 19th Annual Virtual Needham Healthcare Conference

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") today announced that Daphne Zohar, founder and chief executive officer, will present at the 19th Annual Virtual Needham Healthcare Conference on Wednesday, 15 April, at 1:30 PM EDT. The conference is being held virtually, and a webcast of the presentation will be available on the Investors Relations section of the PureTech website at https://www.puretechhealth.com/reports-presentations.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

 

US media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

Tom Donovan

+1 857 559 3397

tom@tenbridgecommunications.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFFFELSLILLII
Date   Source Headline
16th Jun 20207:00 amRNSAkili Granted FDA Clearance for ADHD Treatment
15th Jun 202012:07 pmRNSSecond Price Monitoring Extn
15th Jun 202012:02 pmRNSPrice Monitoring Extension
12th Jun 202012:08 pmRNSSecond Price Monitoring Extn
12th Jun 202012:03 pmRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSResult of AGM
10th Jun 202012:08 pmRNSSecond Price Monitoring Extn
10th Jun 202012:02 pmRNSPrice Monitoring Extension
9th Jun 20207:00 amRNSPositive Data from Vedanta IBD Clinical Studies
4th Jun 20207:00 amRNSPositive FDA Feedback on Follica
2nd Jun 20207:00 amRNSGelesis Approved to Market Plenity in Europe
28th May 20207:00 amRNSPRTC Targets COVID-19 Post-Recovery Complications
27th May 20207:00 amRNSPRTC to Present at Jefferies Virtual Conference
26th May 20201:05 pmRNSVor Appoints CFO Nathan Jorgensen
26th May 20207:00 amRNSPRTC Receives Another $45M from Affiliate Shares
22nd May 202012:02 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:00 amRNSPDMR Notification – Transfer From Trust
19th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 202012:02 pmRNSPrice Monitoring Extension
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
15th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
6th May 202012:07 pmRNSSecond Price Monitoring Extn
6th May 202012:02 pmRNSPrice Monitoring Extension
4th May 202012:02 pmRNSPrice Monitoring Extension
23rd Apr 202012:07 pmRNSSecond Price Monitoring Extn
23rd Apr 202012:03 pmRNSPrice Monitoring Extension
22nd Apr 202011:00 amRNSAkili ADHD Treatment Now Available in US
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 202012:07 pmRNSSecond Price Monitoring Extn
21st Apr 202012:02 pmRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSPRTC to Present at Virtual Needham Conference
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:35 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSFinal Results
1st Apr 20204:41 pmRNSSecond Price Monitoring Extn
1st Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20204:42 pmRNSSecond Price Monitoring Extn
27th Mar 20204:37 pmRNSPrice Monitoring Extension
24th Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:16 amRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:37 pmRNSPrice Monitoring Extension
10th Mar 202010:00 amRNSGelesis: World’s Most Innovative Companies List
10th Mar 20207:00 amRNSNotice of Results
9th Mar 20204:41 pmRNSSecond Price Monitoring Extn
9th Mar 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.